🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

JPMorgan sees recent Eli Lilly weakness as opportunity ahead of donanemab ph3 data

Published 03/09/2023, 01:01 PM
Updated 03/09/2023, 01:06 PM
©  Reuters J.P. Morgan sees recent Eli Lilly (LLY) weakness as opportunity ahead of Donanemab Ph3 Data
LLY
-

By Michael Elkins

JPMorgan reiterated an Overweight rating and a $400.00 price target on Eli Lilly and Company (NYSE:LLY) ahead of the upcoming release of the donanemab ph3 data.

Analysts there wrote in a note, “Following recent LLY weakness, we have been receiving a number of questions on the story and wanted to provide our updated thoughts on upcoming donanemab ph3 data as well as Mounjaro & the broader incretin portfolio. Overall, we see the LLY story as very much on track and LLY remains one of our favorite names in the group. With shares now trading at ~25.5x our 2024 EPS (despite a 20%+ EPS CAGR over the next decade), we would take advantage of volatility ahead of donanemab data to build positions.”

The analysts see a favorable risk-reward into the upcoming donanemab Ph3 data, with shares reflecting only marginal value for the asset. Heading into TB-2, they see three broad potential outcomes. First, JPMorgan’s base case, donanemab shows data comparable to lecanemab. With mid-to-high 20’s cognitive benefit and manageable symptomatic ARIA-e rates. In this case, they see the stock up 15% or more. In the event of mixed results, LLY is expected to be down slightly to up 5-10%. If donanemab fails, they expect shares to trade down ~8-10% and quickly rebound with the story shifting to a pure play diabetes/obesity stock.

JPMorgan sees donanemab as a ~$10-15 billion opportunity in Alzheimer’s. They see the Alzheimer’s market as reaching ~$25B in annual sales and (assuming positive results) expect donanemab to take ~60% of the market equating to a ~$100/share of value for LLY.

Shares of LLY are up 1.60% in mid-day trading on Thursday.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.